Tannenbaum Helpern Syracuse & Hirschtritt, LLP
About Us Careers Contact Us Search
Home Practice Areas Industries Case Results Attorneys Publications Events Press Room


Gerard F. Diebner


Counsel
diebner@thsh.com
Phone: 212-508-7533



Attorneys » D » Gerard F Diebner

Gerard F Diebner

Bio

Gerard F. Diebner has over 25 years of experience in the field of patent law. His practice concentrates in the areas of pharmaceuticals, biotechnology, chemistry, medical devices, cosmetics, agriculture, veterinary products, pollution control, clean energy and business methods.

Mr. Diebner has extensive trial experience both before the Federal District Courts and the ITC. He also handles patent issues concerning mergers and acquisitions and due diligence searches, and provides general intellectual property corporate advice. He drafts and prosecutes patent applications before the U.S. Patent and Trademark Office and has substantial experience with interference practice. Mr. Diebner works with individual inventors, start-up corporations in emerging growth industries and established multi-national companies.

Mr. Diebner was involved with one of the first biotechnology lawsuits ever brought and was successful in one of the longest biotechnology cases tried to a jury. Mr. Diebner was also involved with Novo Nordisk's successful litigation against Genentech concerning human growth hormone and with representing Merck against Searle in a patent interference, where it was held that Merck, not Searle, was the first to invent VIOXX. Mr. Diebner was lead trial counsel for Proveris Scientific Corp. in Proveris v. Innovasystems, which established that the use of a patent laboratory instrument for the purpose of obtaining FDA approval for a drug product did not fall within the sale harbor provision of 35 U.S.C. §271(e)(1).

Significant Matters

  • Ortho v. Becton, Dickenson Co. - heralded as "the first cannon shot of the biotechnology era". Settled favorably for client Ortho.
  • In re Nifedipine - defended Pfizer's nifedipine patent against numerous generic drug companies.
  • Xoma v. Centacor - one of the longest biotechnology patent cases tried to a jury, verdict of patent validity and infringement returned for client Xoma after six months of trial.
  • Genentech v. Novo Nordisk - successfully defended Novo Nordisk against infringement suit by Genentech for recombinant human growth hormone. In this case, for the first (and only) time, the Federal Circuit not only vacated a preliminary injunction, it declared the underlying patent invalid.
  • Merck v. Searle - successfully defended Merck's patent covering VIOXX in an Interference proceeding and subsequent litigation where Searle contended it was the first inventor.
  • Proveris v. Innovasystems - first chair for a one week jury trial before the Federal District Court in Boston, where the jury returned a verdict in favor of our client Proveris. Case established that the use of a patented laboratory instrument used to obtain FDA approval for a drug product did not fall within the safe harbor provision of 35 U.S.C.
  • Due diligence review of patent portfolio of target company on behalf of a major U.S. pharmaceutical company.
  • Due diligence review of patent portfolio for foreign (India) generic pharmaceutical companies seeking to purchase U.S. pharmaceutical companies.

Gerard Diebner has or will serve as a speaker, moderator, event chair or panelist for the following event:

Practice Areas:

Areas of Focus:

  • Patents

Education:

College:

  • St. John's University, 1978, B.S.-Pharmacy

Law School:

  • St. John's University, 1983, J.D.

Memberships:

  • AIPLA
  • PLI

Bar Admissions:

  • New York
  • U.S. Patent and Trademark Office

Award Recognitions:

  • Super Lawyers: 2014-2016
Like us on FaceBook Follow us on Twitter Get LinkedIn with us Pin It! Email Us Print this Page

Sitemap | Terms of Use | Privacy | Attorney Advertising

Tannenbaum Helpern Syracuse & Hirschtritt LLP provides legal advice only to individuals or entities with which it has established an attorney-client relationship and such advice is based on the particular facts and circumstances of each matter. Contacting us through this site, or otherwise, will not establish an attorney-client relationship with us. Any e-mail or other communication sent to THSH or its lawyers through this site will not be treated as subject to the attorney-client privilege or as otherwise confidential and you should not include any confidential information in any such communication.